Picture loading failed.

Anti-GD2;CD3E therapeutic antibody (Pre-made Nivatrotamab biosimilar,Bispecific Mixed mAb and scFv) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Nivatrotamab, a humanized bispecific anti-GD2 antibody, is currently in Phase 1 clinical development in collaboration with Memorial Sloan Kettering Cancer Center (“MSK”) in patients with relapsed/refractory neuroblastoma, as well as high grade osteosarcoma and other GD2(+) solid tumors, where patients have relapsed or refractory disease that is resistant to standard therapy.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-380-1mg 1mg Inquiry
GMP-Bios-ab-380-10mg 10mg Inquiry
GMP-Bios-ab-380-100mg 100mg Inquiry
GMP-Bios-ab-380-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-GD2;CD3E therapeutic antibody (Pre-made Nivatrotamab biosimilar,Bispecific Mixed mAb and scFv)
INN Name Nivatrotamab
TargetGD2;CD3E
FormatBispecific Mixed mAb and scFv
DerivationBispecific antibody
Species ReactivityHuman
CH1 IsotypeIgG1;na
VD LCKappa;Kappa
Highest_Clin_Trial (Jan '20)Phase-I/II
Est. StatusActive
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2020
Year Recommendedna
CompaniesMemorial Sloan-Kettering Cancer Center
Conditions Approvedna
Conditions ActiveNeuroblastoma
Conditions Discontinuedna
Development Techna